Glipizide

Generic Name
Glipizide
Brand Names
Glucotrol
Drug Type
Small Molecule
Chemical Formula
C21H27N5O4S
CAS Number
29094-61-9
Unique Ingredient Identifier
X7WDT95N5C
Background

Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea ...

Indication

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

Phase 4
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Glipizide and Glargine
Drug: Glipizide
First Posted Date
2008-08-12
Last Posted Date
2008-08-12
Lead Sponsor
Cook County Health
Target Recruit Count
80
Registration Number
NCT00732524
Locations
🇺🇸

John H Stroger Hospital Of Cook County, Chicago, Illinois, United States

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Alogliptin
Drug: Glipizide
First Posted Date
2008-07-02
Last Posted Date
2013-05-24
Lead Sponsor
Takeda
Target Recruit Count
441
Registration Number
NCT00707993

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

First Posted Date
2008-04-17
Last Posted Date
2015-03-30
Lead Sponsor
AstraZeneca
Target Recruit Count
1217
Registration Number
NCT00660907
Locations
🇬🇧

Research Site, Trowbridge, United Kingdom

Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease

First Posted Date
2007-08-08
Last Posted Date
2011-04-26
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
304
Registration Number
NCT00513630
Locations
🇨🇳

Shanghai Jiao Tong University School of Medicine, Shanghai, China

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

First Posted Date
2007-07-31
Last Posted Date
2017-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
129
Registration Number
NCT00509236

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

First Posted Date
2007-07-31
Last Posted Date
2017-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
426
Registration Number
NCT00509262

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

First Posted Date
2006-07-11
Last Posted Date
2017-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
262
Registration Number
NCT00350779

Insulin Glargine in Type 2 Diabetic Patients

First Posted Date
2006-07-04
Last Posted Date
2009-09-15
Lead Sponsor
Sanofi
Target Recruit Count
387
Registration Number
NCT00347100
Locations
🇨🇳

Sanofi-Aventis, Beijing, China

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Phase 3
Completed
Conditions
Atherosclerosis
Interventions
Drug: rosiglitazone maleate
Drug: Glipizide
First Posted Date
2005-07-01
Last Posted Date
2017-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
672
Registration Number
NCT00116831
Locations
🇹🇭

GSK Investigational Site, Chiang Mai, Thailand

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

First Posted Date
2004-11-01
Last Posted Date
2015-04-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
91
Registration Number
NCT00095056
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy